Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non-small-cell lung cancer with or without prior crizotinib therapy-Reference-Cited by-同舟云学术

Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non-small-cell lung cancer with or without prior crizotinib therapy

Published:2016-11 Issue:11 Volume:107 Page:1642-1646
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Hida Toyoaki¹,Nakagawa Kazuhiko²,Seto Takashi³,Satouchi Miyako⁴,Nishio Makoto⁵,Hotta Katsuyuki⁶,Takahashi Toshiaki⁷,Ohe Yuichiro⁸⁹,Takeda Koji¹⁰,Tatsuno Masahiro¹¹,Asakawa Takashi¹²,Shimada Tadashi¹²,Tanaka Tomohiro¹²,Tamura Tomohide⁸¹³

Affiliation:

1. Department of Thoracic Oncology; Aichi Cancer Center; Nagoya Japan

2. Department of Medical Oncology; Kindai University Faculty of Medicine; Osaka Japan

3. Department of Thoracic Oncology; National Kyusyu Cancer Center; Fukuoka Japan

4. Department of Thoracic Oncology; Hyogo Cancer Center; Akashi Japan

5. Department of Thoracic Medical Oncology; The Cancer Institute Hospital of Japanese Foundation for Cancer Research; Tokyo Japan

6. Department of Allergy and Respiratory Medicine; Okayama University Hospital; Okayama Japan

7. Department of Thoracic Oncology; Shizuoka Cancer Center; Shizuoka Japan

8. Department of Thoracic Oncology; National Cancer Center Hospital; Tokyo Japan

9. National Cancer Center East; Chiba Japan

10. Department of Medical Oncology; Osaka City General Hospital; Osaka Japan

11. Translational Clinical Research Science & Strategy Department; Chugai Pharmaceutical Co. Ltd.; Tokyo Japan

12. Clinical Science & Strategy Department; Chugai Pharmaceutical Co. Ltd.; Tokyo Japan

13. Thoracic Center; St. Luke's International Hospital; Tokyo Japan

Funder

Chugai Pharmaceutical Co. Ltd.

Pfizer

Novartis

Novartis Pharma

Astellas Pharma

AstraZeneca

Ono Pharmaceutical

Bristol-Myers Squibb

Eli Lilly Japan

Taiho Pharmaceutical

Meso Scale Diagnostics

Takeda Pharmaceutical Company

Daiichi Sankyo Company

Quintiles

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/cas.13066/fullpdf

Reference20 articles.

1. Ferlay J Soerjomataram I Ervik M et al GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 Lyon, France International Agency for Research on Cancer 2013 http://globocan.iarc.fr

2. Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors;Chia;Clin Epidemol,2014

3. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-hodgkin's lymphoma;Morris;Science,1994

4. Mechanistic insight into the ALK receptor tyrosine kinase in human cancer biology;Hallberg;Nat Cancer Rev,2013

5. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost–effectiveness of ensartinib for patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer in China;Journal of Comparative Effectiveness Research;2022-08

2. Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET);Translational Lung Cancer Research;2021-01

3. Alectinib for relapsed or refractory anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma: An open‐label phase II trial;Cancer Science;2020-10-28

4. ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis;PLOS ONE;2020-02-19

5. Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non‐EML4‐ALK rearrangements detected from cerebrospinal fluid: A case report;Thoracic Cancer;2019-11-25